F4 FundFund
TeamPortfolioRaiseChampionsEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investorsSimilar Firms
Hot Fund

Define Ventures

definevc.com · San Francisco, California

“Healthcare's future will be defined by the convergence of technology innovation, consumer preferences, and industry transformation. We partner with entrepreneurs who combine deep healthcare domain expertise with technical excellence to build category-defining companies.”

$750K – $6M
Check Size
Leads
Lead Tendency
$800M
AUM
~2 Weeks
Timeline
01Investment Thesis

Healthcare's future will be defined by the convergence of technology innovation, consumer preferences, and industry transformation. We partner with entrepreneurs who combine deep healthcare domain expertise with technical excellence to build category-defining companies.

Exclusion Criteria

We do not invest in non-healthcare sectors. We focus on founders with both healthcare understanding and technical capability.

02Investment Team
LC
Lynne Chou O'Keefe
Founder & Managing Partner
BB
Bruce Broussard
Venture Partner
FW
Frank Williams
Venture Partner
CM
Carolyn Magill
Venture Partner
CS
Chirag Shah
Partner
HT
Hong Truong
Principal
CE
Chuka Esiobu
Principal
GH
Garrett Howard
Senior Associate
03F4 Research Brief

Define Ventures Research

Executive Summary

Define Ventures is one of the largest venture capital firms exclusively focused on early-stage digital health companies. Founded by Lynne Chou O'Keefe, the firm manages $800 million in assets under management across six funds and has established itself as a category-defining investor in healthcare technology. The firm combines deep healthcare expertise with a technology-driven mindset, creating a powerful partnership model for healthcare entrepreneurs.

Investment Thesis

Define Ventures operates on a foundational belief that the future of healthcare will be fundamentally transformed by the convergence of rapid technology innovation, evolving consumer preferences, and seismic shifts within the healthcare industry itself. The firm explicitly aims to partner with entrepreneurs who can bridge the gap between deep understanding of healthcare ecosystem complexities and modern technology solutions.

The firm's philosophy emphasizes that healthcare innovation requires more than just capital—it demands operational expertise, access to healthcare decision-makers, and strategic guidance from leaders who have built category-defining companies at scale. Define Ventures positions itself as a true operating partner committed to driving measurable shareholder value through network leverage, strategic relationships, and hands-on support.

Sector and Stage Focus

Primary Sector: Digital Health / Healthcare Technology

Define Ventures invests exclusively in the healthcare sector, with particular emphasis on:

  • Digital health platforms - Direct-to-consumer and B2B2C health technology
  • Value-based care enablement - Technology for healthcare providers and payers
  • Healthcare infrastructure - Clinical operations, data, and workflow optimization
  • AI/ML in healthcare - Emerging applications transforming clinical and administrative functions
  • Population health - Employer, payer, and provider solutions for managing health outcomes

Investment Stages

Define Ventures invests across the full spectrum:

  • Pre-seed / Incubation (through in-house incubator)
  • Seed stage ($1M-$5M typical)
  • Series A ($5M-$15M typical)
  • Selective Series B follow-ons

The firm operates a structured incubation program and runs an AI Fellows program that identifies and trains next-generation healthcare AI founders.

Portfolio Highlights

Public Companies:

  • Hims & Hers (NYSE: HIMS) - Direct-to-consumer health and wellness platform, primary success

Category-Defining Companies:

  • Unite Us - Community health platform connecting individuals to services
  • Cohere Health - AI/ML for clinical approval and administrative automation
  • FOLX Health - LGBTQIA+ specialized digital health platform
  • Centivo - Self-funded employer health plans
  • Blackbird Health - Mental healthcare for young people
  • Tia - Women's health clinic model
  • Found - Weight care and metabolic health platform
  • Story Health - Home-based health coaching with AI clinical support

AI/Automation Focus:

  • Layer Health - Clinical data extraction and understanding
  • Hyro - Healthcare conversational AI
  • Solara Health - AI-driven clinical workforce automation
  • Luminai - Business process automation for healthcare
  • Laudio - Healthcare workforce retention through AI

Clinical Trial & Life Science:

  • Crescendo Health - Real-world data for clinical trials
  • Lightship - Hybrid clinical trial operations
  • Double Blind Bio - Clinical trial site automation
  • Verana Health - Real-world clinical data insights

Enterprise/Payer Solutions:

  • Dexcare - Patient access optimization
  • Fair Square Medicare - Medicare sales automation
  • Marit Health - Clinician compensation transparency

Team and Leadership

Define Ventures is led by Lynne Chou O'Keefe (Founder & Managing Partner) with support from Venture Partners Bruce Broussard, Frank Williams, and Carolyn Magill. The firm maintains a best-in-class advisory board including healthcare titans (Toby Cosgrove - Cleveland Clinic, Peter Fine - Banner Health, Beth Bierbower - Humana) and technology leaders (Jia Li - Google AI/ML, Ashley Yuki Alexander - OpenAI Healthcare Head).

Geographic Focus

Based in San Francisco, California, with US-wide investment scope.

Lead Tendency

Define Ventures is a lead investor that actively drives governance and strategic decisions. The firm takes board seats and provides direct access to healthcare system relationships (72% of portfolio companies have customers within Define's coalition of healthcare organizations). Portfolio support includes talent recruitment (2 in 3 companies have senior talent placements) and capital raising support ($1.6B raised by portfolio companies in follow-on funding).

Recent Activity

Define Ventures maintains active deployment with recent investments in 2025 including Hyro (October 2025) and Layer Health (December 2025). The fund has established itself as thought leader on healthcare AI with market research publications through their AI + Healthcare Summit.

Fund Performance

  • AUM: $800 million across 6 funds
  • Exit Value: $23 billion cumulatively
  • Portfolio Companies: 60+ active investments plus stealth/incubation
  • IPO Success: Hims & Hers (NYSE: HIMS) represents major public company success

Conclusion

Define Ventures combines singular healthcare sector focus, substantial capital scale, proven returns, and operational leverage through direct healthcare system relationships. The firm represents the gold standard for early-stage healthcare venture capital and serves as strategic operating partner for healthcare entrepreneurs with technical excellence and domain expertise.

04Selected Portfolio
Biotech & Life Sciences
Valius Sciences
E-commerce & Marketplaces
9am Health
Enterprise Software
Tia·Luminai
Fintech & Payments
Found
Healthcare & Digital Health
Hims & Hers·Unite Us·Cohere Health·Folx Health·Centivo·Blackbird Health·Story Health·Layer Health·Hyro·Solara Health·Laudio·Verana Health·Dexcare·Fair Square Medicare·Concert Health·Waltz Health·Foundation Health·9amHealth·Arintra
Manufacturing & Industrial
Lightship
Other
Crescendo Health·Double Blind Bio·Marit Health
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (18) →
Define Ventures led Arintra's $25M Series B for its AI-driven medical coding and revenue assurance platform.
INVESTMENT·fiercehealthcare.com+1
AUG 26, 2026
Define Ventures published a portfolio spotlight on Arintra, an enterprise-grade autonomous medical coding platform powering coding at leading health systems.
MILESTONE·definevc.com
AUG 26, 2026
Led 9amHealth's $26M Series B for AI-driven virtual specialty care for chronic conditions.
INVESTMENT·hlth.com+1
MAY 14, 2026
Define Ventures led 9amHealth's $26M Series B to expand its virtual specialty care platform for cardiometabolic conditions.
INVESTMENT·fiercehealthcare.com
MAY 13, 2026
Published comprehensive AI investing thesis outlining framework for healthcare transformation across four layers: front-door personalization, data foundation, insight extraction, and workflow automation.
ESSAY·definevc.com
Added recently
06Frequent co-investors
7V
7wire Ventures
Both backed 2 of the same companies
9am Health, Folx Health
A
Atomic
Both backed 2 of the same companies
Found, Hims & Hers
CV
Calm/Storm Ventures
Both backed 2 of the same companies
9amHealth, Foundation Health
FC
Flare Capital Partners
Both backed 2 of the same companies
Cohere Health, Layer Health
FC
Frist Cressey Ventures
Both backed 2 of the same companies
Dexcare, Blackbird Health
Find the investors for your round→
07Similar Firms
VV
Virtue VC
$500K – $4M · Pre-Seed · Seed
→
MS
Meridian Street Capital
$100K – $5M · Pre-Seed · Seed
→
SV
SpringTide Ventures
$500K – $5M · Pre-Seed · Seed
→
MV
MedMountain Ventures
$500K – $5M · Pre-Seed · Seed
→
FC
Flare Capital Partners
$1M – $10M · Seed · Series A
→
Quick Reference
Check Size
$750K – $6M
Stages
Pre-Seed · Seed · Series A
AUM
$800M
Decision
Partnership · ~2 Weeks
Warm Intro
Not Required
Involvement
Board Seat
Location
San Francisco, California
Sector Focus
Biotech & Life SciencesEnterprise SoftwareHealthcare & Digital Health
Models
Digital HealthHealthcare TechnologyValue-Based Care
Technology
AI/MLData AnalyticsHealthcare Automation
See all Biotech & Life Sciences investors →See all Enterprise Software investors →See all Healthcare & Digital Health investors →
Visit definevc.com ↗

See how Define Ventures matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Biotech & Life SciencesEnterprise SoftwareHealthcare & Digital Health

See how Define Ventures matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched August 30, 2026F4 Research Engine